COPENHAGEN, Denmark, Sept. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY - News) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) today announced results from a study indicating that exenatide improves blood sugar levels as effectively as biphasic insulin aspart 30/70 (NovoMix 30®, NovoNordisk) for people with type 2 diabetes failing to achieve acceptable blood sugar control on both metformin and a sulfonylurea, two common oral diabetes medications. This long-term clinical trial is the second study conducted at European clinical centers demonstrating that exenatide can control blood sugar as effectively as insulin.(1)
